Oryzon Genomics SA
MAD:ORY

Watchlist Manager
Oryzon Genomics SA Logo
Oryzon Genomics SA
MAD:ORY
Watchlist
Price: 1.558 EUR -0.76% Market Closed
Market Cap: 99.4m EUR
Have any thoughts about
Oryzon Genomics SA?
Write Note

Oryzon Genomics SA
Cash from Financing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Oryzon Genomics SA
Cash from Financing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
Oryzon Genomics SA
MAD:ORY
Cash from Financing Activities
€6m
CAGR 3-Years
-31%
CAGR 5-Years
-3%
CAGR 10-Years
N/A
Grifols SA
MAD:GRF
Cash from Financing Activities
€186m
CAGR 3-Years
N/A
CAGR 5-Years
4%
CAGR 10-Years
N/A
Pharma Mar SA
MAD:PHM
Cash from Financing Activities
-€15.9m
CAGR 3-Years
13%
CAGR 5-Years
-3%
CAGR 10-Years
-7%
Biotechnology Assets SA
MAD:BST
Cash from Financing Activities
-€365.8k
CAGR 3-Years
82%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Oryzon Genomics SA
Glance View

Market Cap
98.1m EUR
Industry
Biotechnology

Oryzon Genomics SA is a clinical stage biopharmaceutical company, which engages in the discovery, research, and development of new chemical entities, as well as conducting clinical trials. The company is headquartered in Cornella De Llobregat, Barcelona and currently employs 44 full-time employees. The company went IPO on 2015-12-10. Its compounds in clinical development include iadademstat (ORY-lOOl), an LSD1 inhibitor that is in Phase II trials for the treatment of acute myeloid leukemia and small cell lung cancer; and vafidemstat (ORY-2001), an LSD1 inhibitor optimized for the Central Nervous System (CNS), in multiple Phase II clinical trials for the treatment of CNS and psychiatric illnesses. The firm also has ORY-3001, in preclinical development for the treatment of non-oncological diseases and has additional programs to develop inhibitors against other epigenetic targets.

ORY Intrinsic Value
1.446 EUR
Overvaluation 7%
Intrinsic Value
Price

See Also

What is Oryzon Genomics SA's Cash from Financing Activities?
Cash from Financing Activities
6m EUR

Based on the financial report for Dec 31, 2023, Oryzon Genomics SA's Cash from Financing Activities amounts to 6m EUR.

What is Oryzon Genomics SA's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
-3%

Over the last year, the Cash from Financing Activities growth was -31%. The average annual Cash from Financing Activities growth rates for Oryzon Genomics SA have been -31% over the past three years , -3% over the past five years .

Back to Top